Loading
Animal Virus Infections Studies / Virus-based Gene Therapy Research / Cancer Research and Treatments · Journal article
Frontiers in Oncology · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single-case report of a 58-year-old woman with platinum-relapsed SCLC who achieved a partial response and 16.7-month progression-free survival after Olvi-Vec oncolytic immunotherapy followed by platinum re-challenge. The case illustrates a potentially favourable outcome in a resistant population but provides no evidence sufficient to establish efficacy or guide practice, pending results from the ongoing Phase Ib trial.
Single-case report from an ongoing Phase Ib trial. 58-year-old woman enrolled in ongoing Phase Ib trial of Olvi-Vec; platinum-relapsed/refractory advanced small cell lung cancer; prior progression on frontline platinum and etoposide.. Intervention: Single course of Olvi-Vec (modified oncolytic vaccinia virus) followed by re-challenge with platinum-based therapy. n = 1.
84.6% reduction in target lesion size following Olvi-Vec and platinum re-challenge Progression-free survival of 16.7 months in a platinum-relapsed patient Olvi-Vec was well tolerated
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This case cannot guide clinical practice on its own. It raises the hypothesis that Olvi-Vec may sensitize platinum-relapsed SCLC to re-challenge therapy through tumour microenvironment modulation, but confirmation requires completion and reporting of the Phase Ib trial with adequate sample size and control comparisons.
A single-case report from an ongoing Phase Ib trial describing one patient's response; while the outcome is noteworthy, case reports lack comparison groups and generalizability to support clinical practice change.
As stated by the source record.
Quoted from the source exactly as published.
This case cannot guide clinical practice on its own. It raises the hypothesis that Olvi-Vec may sensitize platinum-relapsed SCLC to re-challenge therapy through tumour microenvironment modulation, but confirmation requires completion and reporting of the Phase Ib trial with adequate sample size and control comparisons.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Oncolytic viral therapy has broad antitumor and immuno-oncology effects that may be useful in managing malignancies, particularly in relapsed or refractory diseases following conventional therapeutic regimens. We report a case involving a patient enrolled in an ongoing phase Ib clinical trial of Olvi-Vec, a modified oncolytic vaccinia virus, in patients with platinum-relapsed/refractory advanced small cell lung cancer (SCLC). In this 58-year-old woman who had progressed after frontline treatment with platinum and etoposide, a deep and durable partial objective response (84.6% reduction in target lesion size) and progression-free survival (16.7 months) were observed following a single course of Olvi-Vec followed by re-challenge with platinum-based therapy. These findings exceed expected clinical outcomes based on historical data. Olvi-Vec therapy was well tolerated. The clinical effect observed in this patient may be related to Olvi-Vec-mediated changes in the tumor microenvironment, potentially leading to platinum re-sensitization. The results of this case report indicate that the role of Olvi-Vec as an oncolytic immunotherapy for cancer treatment warrants additional study.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.